X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
enzalutamide (1250) 1250
prostate cancer (842) 842
index medicus (839) 839
humans (725) 725
male (693) 693
oncology (575) 575
abiraterone (566) 566
chemotherapy (418) 418
prostatic neoplasms, castration-resistant - drug therapy (402) 402
increased survival (401) 401
docetaxel (387) 387
abiraterone acetate (359) 359
androgen receptor (354) 354
urology & nephrology (327) 327
metastasis (318) 318
cancer (296) 296
phenylthiohydantoin - analogs & derivatives (285) 285
prostatic neoplasms, castration-resistant - pathology (247) 247
androgens (242) 242
castration-resistant prostate cancer (232) 232
castration (216) 216
aged (215) 215
survival (209) 209
prostate (205) 205
care and treatment (195) 195
treatment outcome (188) 188
middle aged (187) 187
antineoplastic agents - therapeutic use (183) 183
receptors, androgen - metabolism (182) 182
men (172) 172
prednisone (163) 163
therapy (162) 162
animals (161) 161
cell line, tumor (160) 160
phenylthiohydantoin - therapeutic use (158) 158
cabazitaxel (157) 157
double-blind (157) 157
antitumor-activity (155) 155
mitoxantrone (155) 155
expression (146) 146
receptors, androgen - genetics (142) 142
resistance (134) 134
aged, 80 and over (133) 133
prostatic neoplasms - drug therapy (132) 132
progression (130) 130
analysis (126) 126
article (123) 123
cancer therapies (118) 118
neoplasm metastasis (116) 116
research (115) 115
urology (113) 113
prostatic neoplasms - pathology (112) 112
disease-free survival (111) 111
drug therapy (110) 110
antiandrogen (107) 107
metastases (106) 106
androgen antagonists - therapeutic use (105) 105
drug resistance, neoplasm (104) 104
prostatic neoplasms, castration-resistant - metabolism (104) 104
prostatic neoplasms, castration-resistant - genetics (100) 100
phenylthiohydantoin - pharmacology (99) 99
patients (98) 98
development and progression (97) 97
disease progression (97) 97
splice variants (94) 94
pharmacology & pharmacy (93) 93
prostate-specific antigen - blood (93) 93
mice (92) 92
cell biology (90) 90
retrospective studies (90) 90
taxoids - therapeutic use (87) 87
prognosis (86) 86
prostatic neoplasms, castration-resistant - blood (86) 86
endocrinology & metabolism (84) 84
health aspects (83) 83
metastatic castration-resistant prostate cancer (83) 83
survival analysis (81) 81
tumors (80) 80
mitoxantrone plus prednisone (79) 79
plus prednisone (79) 79
medicine & public health (78) 78
antineoplastic combined chemotherapy protocols - therapeutic use (77) 77
bicalutamide (77) 77
clinical trials (76) 76
prostatic neoplasms, castration-resistant - mortality (76) 76
ar-v7 (74) 74
urologic and male genital diseases (74) 74
trial (73) 73
antineoplastic agents - pharmacology (72) 72
gene expression (71) 71
clinical activity (69) 69
prostatic neoplasms - metabolism (68) 68
resistant prostate-cancer (68) 68
open-label (67) 67
signal transduction - drug effects (67) 67
cells (65) 65
mutation (64) 64
drug resistance (63) 63
genetic aspects (63) 63
inhibition (63) 63
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1243) 1243
German (52) 52
French (29) 29
Spanish (17) 17
Russian (12) 12
Czech (6) 6
Hungarian (5) 5
Japanese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
EUROPEAN UROLOGY, ISSN 0302-2838, 01/2015, Volume 67, Issue 1, pp. 30 - 32
Journal Article
ONCOLOGIE, ISSN 1292-3818, 01/2016, Volume 18, Issue 1, pp. 76 - 78
Journal Article
European urology, ISSN 0302-2838, 06/2019
Wnt signaling is a cellular pathway involved in embryogenesis, development, and neoplasia. Wnt-pathway activation may accelerate prostate cancer... 
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 68, Issue 1, pp. 147 - 153
Journal Article
BULLETIN DU CANCER, ISSN 0007-4551, 09/2016, Volume 103, Issue 9, pp. 711 - 713
Journal Article
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 01/2017, Volume 58, Issue 1, pp. 85 - 90
Lu-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration resistant prostate cancer... 
STATISTICS | DOCETAXEL | mCRPC | prostate cancer | PSMA | GA-68-PSMA LIGAND | PSMA-617 | radioligand therapy | CLINICAL-TRIALS | PET/CT | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | ENZALUTAMIDE | ABIRATERONE
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4, pp. 376 - 382
Purpose We evaluated the relationship between prostate-specific antigen (PSA) and overall survival in the context of a prospectively randomized clinical trial... 
PREDNISONE | MITOXANTRONE | ONCOLOGY | INCREASED SURVIVAL | CHEMOTHERAPY | ENZALUTAMIDE | ABIRATERONE | ORIGINAL REPORTS
Journal Article
The Journal of Molecular Diagnostics, ISSN 1525-1578, 05/2018, Volume 20, Issue 3, pp. 316 - 325
Recent reports have emphasized the clinical relevance of detecting in circulating tumor cells (CTCs). Our aim was to set up a validated multicenter pipeline to... 
PATHOLOGY | RESISTANT PROSTATE-CANCER | MEN | ENZALUTAMIDE | ABIRATERONE
Journal Article
Cancer Research, ISSN 0008-5472, 2018, Volume 78, Issue 20, pp. 5731 - 5740
Advanced prostate cancer initially responds to androgen deprivation therapy (ADT), but the disease inevitably recurs as castration-resistant prostate cancer... 
ONCOLOGY | INCREASED SURVIVAL | PROTEINS | PROGRESSION | CHEMOTHERAPY | ENZALUTAMIDE | EZH2 | ABIRATERONE
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 67, Issue 1, pp. 53 - 60
Abstract Background Enzalutamide is a novel antiandrogen with proven efficacy in metastatic castration-resistant prostate cancer (mCRPC). Objective To evaluate... 
Urology | Castration-resistant prostate cancer | Primary resistance to enzalutamide | Androgen signaling inhibition | Bone metastasis | Bone tumor microenvironment | Adaptive feedback mechanism | Androgen receptor | Predictors of outcome | Enzalutamide | Tissue-based research | TESTOSTERONE | CHEMOTHERAPY | RECEPTOR SPLICE VARIANTS | THERAPY | DEPRIVATION | CLINICAL-TRIALS | UROLOGY & NEPHROLOGY | INCREASED SURVIVAL | PROGRESSION | ABIRATERONE | Prospective Studies | Phenylthiohydantoin - therapeutic use | Humans | Middle Aged | Receptors, Androgen - metabolism | Retroviridae Proteins, Oncogenic - metabolism | Bone Neoplasms - secondary | Cytoplasm - metabolism | Drug Resistance, Neoplasm | Ki-67 Antigen - metabolism | Male | Antineoplastic Agents - therapeutic use | Receptors, Glucocorticoid - metabolism | Prostatic Neoplasms, Castration-Resistant - pathology | Bone Neoplasms - metabolism | Cell Nucleus - metabolism | Protein Isoforms - metabolism | Bone Marrow - metabolism | Aged, 80 and over | Adult | Bone Neoplasms - drug therapy | Testosterone - blood | Gene Dosage | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - metabolism | Bone Marrow Neoplasms - secondary | Phenylthiohydantoin - analogs & derivatives | Prostate-Specific Antigen - blood | Receptors, Androgen - genetics | Signal Transduction - drug effects | Bone Marrow Neoplasms - metabolism | Aged | Bone Marrow Neoplasms - drug therapy | Steroid 17-alpha-Hydroxylase - metabolism | Prostate cancer | Metastasis | Index Medicus | Bone marrow biopsy | Androgen | Antiandrogens
Journal Article
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.